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Blood leukocytes recapitulate diabetogenic
peptide–MHC-II complexes displayed in the
pancreatic islets
Anthony N. Vomund1, Cheryl F. Lichti1,3, Orion J. Peterson1, Ana Maria Arbelaez2, Xiaoxiao Wan1,3, and Emil R. Unanue1,3
Assessing the self-peptides presented by susceptible major histocompatibility complex (MHC) molecules is crucial for
evaluating the pathogenesis and therapeutics of tissue-specific autoimmune diseases. However, direct examination of such
MHC-bound peptides displayed in the target organ remains largely impractical. Here, we demonstrate that the blood
leukocytes from the nonobese diabetic (NOD) mice presented peptide epitopes to autoreactive CD4 T cells. These peptides
were bound to the autoimmune class II MHC molecule (MHC-II) I-Ag7 and originated from insulin B-chain and C-peptide. The
presentation required a glucose challenge, which stimulated the release of the insulin peptides from the pancreatic islets.
The circulating leukocytes, especially the B cells, promptly captured and presented these peptides. Mass spectrometry
analysis of the leukocyte MHC-II peptidome revealed a series of β cell–derived peptides, with identical sequences to those
previously identified in the islet MHC-II peptidome. Thus, the blood leukocyte peptidome echoes that found in islets and
serves to identify immunogenic peptides in an otherwise inaccessible tissue.
Introduction
Recognition of tissue-specific antigens is critical for initiating
T cell responses driving autoimmunity. In type 1 diabetes (T1D),
pancreatic islets are targeted by finely programmed autoim-
mune responses, leading to selective demise of the insulin-
producing β cells (Anderson and Bluestone, 2005). The primary
genetic susceptibility of this disease is conferred by variants of the
MHC-II alleles that bind peptide antigens derived from β cells
(Todd et al., 1987; Acha-Orbea and McDevitt, 1987; Miyazaki et al.,
1990). These peptide–MHC-II complexes form the substrates for
immune recognition by autoreactive CD4 T cells, resulting in their
activation. Examining the antigenic entities displayed in the islets
has substantially facilitated our understanding of the autoimmune
process and provided insights into the development of targeted
immunotherapies (Clemente-Casares et al., 2012; Unanue, 2014).
Yet probing these tissue-derived antigens is limited by their
inaccessibility.
Recent investigations examined how β cells convey their
immunological information to the adaptive immune system
(Vomund et al., 2015; Wan et al., 2018). Examining the non-
obese diabetic (NOD) mouse that spontaneously develops auto-
immune diabetes confirmed two sites for presentation of
diabetogenic antigens: the peripheral lymphoid system and the
islet (Wan et al., 2020). Secondary lymphoid tissues, particu-
larly the pancreatic draining LN, are critical for the priming of
the diabetogenic T cells (Höglund et al., 1999; Gagnerault et al.,
2002; Levisetti et al., 2004); the local presentation in islets
further enhances T cell pathogenicity (Melli et al., 2009; Ferris
et al., 2014; Carrero et al., 2017). Peripheral lymphoid tissues
are consistently sensitized by antigenic products secreted from
the β cells obeying glucose stimulation (Wan et al., 2018). These
materials (referred to as secretome) contain catabolized peptide
fragments generated in the β cell crinosomes (Wan et al., 2018), a
set of lysosomal vesicles that degrades excessive insulin granules
to maintain cellular homeostasis (Smith and Farquhar, 1966;
Halban and Wollheim, 1980; Orci et al., 1984). We have identified
immunogenic epitopes from insulin, a prime antigen required for
initiation of diabetes in NOD mice (Nakayama et al., 2005), in the
crinosomes and the secretome (Wan et al., 2018).
Diabetes development in the NOD mouse depends on the
I-Ag7 MHC-II molecule (Lund et al., 1990; Singer et al., 1998;
Gioia et al., 2019), a structural homologue to the human auto-
immune HLA-DQ8 (Corper et al., 2000; Latek et al., 2000; Lee
et al., 2001). Both molecules select a similar repertoire of self-
peptides (Suri et al., 2005). We performed an unbiased analysis
.............................................................................................................................................................................
1Division of Immunobiology, Department of Pathology and Immunology, Washington University School of Medicine, St. Louis, MO; 2Division of Endocrinology, Department
of Pediatrics, Washington University School of Medicine, St. Louis, MO; 3Bursky Center for Human Immunology and Immunotherapy Programs, Washington University
School of Medicine, St. Louis, MO.
Correspondence to Xiaoxiao Wan: wanx@wustl.edu; Emil R. Unanue: unanue@wustl.edu.
© 2021 Vomund et al. This article is available under a Creative Commons License (Attribution 4.0 International, as described at https://creativecommons.org/licenses/by/4.0/).
Rockefeller University Press https://doi.org/10.1084/jem.20202530 1 of 12








niversity In St. Louis Libraries user on 29 April 2021
of the immunopeptidome of islets isolated from NOD mice and
identified β cell–specific peptides bound to I-Ag7 (Wan et al.,
2020). The major peptides that gave rise to autoreactivity de-
rived from the insulin B-chain (InsB) and the C-peptide (InsC),
which were also identified in the MHC-II peptidomes of the
pancreatic draining LN and spleen (Wan et al., 2020). The InsB-
derived sequences were highly compatible with those that
activated HLA-DQ8–restricted CD4 T cells isolated from the
peripheral blood or the islets in patients with T1D (Yang et al.,
2014; Michels et al., 2017; Babon et al., 2016). These findings
highlighted the communication process between the islet and
peripheral lymphoid tissues. In this study, we further investi-
gated whether tissue-derived antigenic information can be
readily acquired at a site of accessibility. We report that upon β
cell degranulation, InsB- and InsC-derived peptides are captured
by circulating leukocytes via binding to their MHC-II molecules.
TheseMHC-II–bound peptides are identical to those identified in
the islet MHC-II peptidome.
Results
Blood leukocytes take up insulin peptides after a
glucose challenge
We administered glucose by i.p. injection and 30 min later
anesthetized the mice and bled them from the heart or the eye.
White blood cells (WBCs) were separated from erythrocytes and
then tested for presentation of various diabetogenic epitopes. Pre-
sentation was probed by CD4 T cell hybridomas recognizing several
I-Ag7–restricted epitopes. Positive responses were indicated by IL-2
production from the T cell hybridomas when cultured with the
blood leukocytes without pulse with exogenous antigens.
Spontaneous presentation of InsB- and InsC-derived epitopes
was observed (Fig. 1). We have previously characterized two
I-Ag7–binding registers centered on the 9–23 segment of InsB
(InsB:9-23) that generated distinct CD4 T cells (Mohan et al.,
2010, 2011; Gioia et al., 2019). The InsB:12-20 register was de-
rived from crinosomes (Wan et al., 2018); this epitope was not
generated by canonical processing of insulin but was only pre-
sented via extracellular binding of free peptides to MHC-II
(Mohan et al., 2010, 2011; Gioia et al., 2019). We have termed it
type B presentation. Supporting their pathogenicity, T cells di-
rected to InsB:12-20 escaped thymic selection, underwent pe-
ripheral priming, and were among the first to enter islets (Mohan
et al., 2013; Wan et al., 2016, 2018; Gioia et al., 2019). A second set of
T cells recognized an alternative register, InsB:13-21, which is pre-
sented via either intracellular processing of insulin or extracellular
peptide binding (Mohan et al., 2010, 2011; Gioia et al., 2019). We
refer to these as the conventional type A T cells. Concerning the
C-peptide, the C-terminal region of the insulin-1 C-peptide (Ins1C)
encompassing residues 51–61 (Ins1C:51-61) was shown to activate
autoreactive CD4 T cells (Halbout et al., 2002; Levisetti et al., 2008;
Wan et al., 2020). Primary CD4 T cell lines reactive to Ins1C:51-61
were able to transfer diabetes inNOD.Rag1−/− recipients (Wan et al.,
2020). In a previous report, we indicated that islets, upon glucose
challenge, released not only insulin, as expected, but also a variety
of free peptides that resulted from catabolism of insulin and the
C-peptide in crinosomes (Wan et al., 2018).
Fig. 1 summarizes all the experiments testing the three
epitopes. The blood leukocytes presented InsB:13-21 (Fig. 1 A)
and InsB:12-20 (Fig. 1 B) to their specific T cells, but only after a
glucose challenge. The responses were low (∼1,000 cpm) but
were completely blocked by addition of the anti–I-Ag7 antibody
(Fig. 1, A and B). Therefore, uptake and presentation were spe-
cifically mediated by the MHC-II molecule. In contrast to the
InsB epitopes, we found a basal level of presentation of the Ins1C:
51-61 epitope from WBCs in mice without glucose challenge
(Fig. 1 C). Such a response was significantly increased by the
glucose challenge (Fig. 1 C). In these experiments, we included
female and male NOD mice of different ages (4–16 wk old), and
no obvious differences were observed.
Presentation of the InsB-derived peptides was not restricted
to the NOD background. WBCs isolated from regular B6 mice
(expressing I-Ab) did not present the InsB:13-21 epitope; by
contrast, positive presentation was observed in blood leukocytes
from B6 mice harboring the I-Ag7 haplotype (B6g7; Fig. 1 D).
These findings are consistent with our previous observation that
crinosomes in B6g7 mice contain immunogenic insulin peptides
able to bind to I-Ag7 (Wan et al., 2018).
We also tested T cells directed to three other diabetes-
relevant epitopes, including the InsB:11-25 peptide (Wan et al.,
2020), the insulin–chromogranin A fused peptide (recognized
by the BDC2.5 T cell; Delong et al., 2016), and the 206–214
peptide from the islet-specific glucose-6-phosphatase catalytic
subunit-related protein (IGRP:206-214) presented by the MHC-I
molecule Kd (recognized by the 8.3 T cell; Lieberman et al.,
2003). T cell responses to these peptides were negative after
glucose challenge (Fig. 1 D).
Time course experiments indicated that the optimal presen-
tation of InsB:13-21 or InsB:12-20 was observed 30–60 min after
the glucose challenge. The responses started to decrease after
60 min and became negative by 180 min (Fig. 1 E). These results
implied a very fast interaction between the release of the peptides
from islets and the development of the peptide–I-Ag7 complex.
In vivo uptake of the insulin molecule by APCs was mediated
by the insulin receptor; after intracellular processing, the InsB:
13-21 epitope was presented (Wan et al., 2018). This epitope was
also presented when APCs encountered exogenous peptides
(Mohan et al., 2010, 2011; Gioia et al., 2019). To test if these
findings apply to blood leukocytes, we administered the specific
insulin receptor blocker S961 before glucose challenge and tested
presentation. S961 reduced the presentation of InsB:13-21 by
∼50% (Fig. 1 F). Thus, this epitope derived from both internal
processing of insulin and direct binding of free peptides. By
contrast, S961 administration had no effect in the presentation of
InsB:12-20 (Fig. 1 F), an epitope that develops from extracellular
peptide binding (Mohan et al., 2010, 2011; Gioia et al., 2019).
These findings reinforce the notion that catabolized peptides in
the crinosomes are an important antigen source that seeds the
periphery upon release from the islets.
Blood B cells primarily capture and present insulin peptides
To identify the MHC-II–bearing APCs in the circulation, we
examined WBCs isolated from 4-wk-old female NOD mice by
flow cytometry. T cells, natural killer cells, and neutrophils
Vomund et al. Journal of Experimental Medicine 2 of 12
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Figure 1. Spontaneous presentation of immunogenic insulin epitopes by blood leukocytes. (A–C) Blood leukocytes were obtained from NOD mice with
or without a prior glucose challenge and were directly cultured with CD4 T cell hybridomas with defined specificities to InsB:13-21 (A), InsB:12-20 (B), and
Vomund et al. Journal of Experimental Medicine 3 of 12
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were excluded from the total CD45+ leukocytes. The re-
maining cells (CD45+Thy1.2–CD49b–Ly6G–) contained B cells
(CD19+B220+), monocytes (Ly6C+CD11b+), plasmacytoid
dendritic cells (pDCs; Ly6C+CD11c+SiglecH+B220+), and con-
ventional DCs (Ly6C–CD11c+; Fig. 2 A). Among these, the
major population was B cells, which ubiquitously expressed
I-Ag7 (Fig. 2 A). By contrast, the monocytes, pDCs, and con-
ventional DCs were limited by cell number, and only a minor
portion of these cells expressed I-Ag7 (Fig. 2 A). Quantification
from multiple experiments showed that the MHC-II–bearing
B cells constituted ∼20% of the CD45+ leukocytes in NOD mice,
whereas other APCs had a minimal presence (Fig. 2 B). Thus,
B cells are the major APCs in the blood.
We next isolated an equal number of B cells and non–B cell
APCs from NOD mice following a glucose challenge and com-
pared their presentation of insulin peptides. Positive responses
from presentation of both InsB:13-21 and InsB:12-20 were de-
tected in the B cells, whereas those from the non–B cell com-
partment were minimal (Fig. 2 C). The circulating B cells highly
expressed MHC-II (Fig. 2 A), which may also contribute to the
presentation process. This was tested by pulsing a high con-
centration of exogenous InsB:9-23 in B cells and non–B cell APCs
isolated from mice without a glucose challenge. The B cells
showed an approximately twofold higher level of presentation to
the InsB:13-21– or the InsB:12-20–specific T cells as compared
with the non–B cells (Fig. 2 D). Collectively, the insulin peptides
Ins1C:51-61 (C). IL-2 production from the culture supernatants was measured to indicate the T cell responses. The dependence of MHC-II was determined by
adding the anti–I-Ag7 blocking antibody to the culture. (D) Responses of T cell hybridomas with indicated antigen specificities to blood leukocytes obtained
from B6, B6g7, or NOD mice. (E) Responses of the InsB:13-21– and InsB:12-20–specific CD4 T cells to blood leukocytes obtained from NOD mice at the
indicated time points after the glucose challenge. (F) Responses of the InsB:13-21– (top) and InsB:12-20– (bottom) specific CD4 T cells to blood leukocytes
obtained from NOD mice with or without injection of the insulin receptor blocker S961, followed by glucose challenge. Data (mean ± SEM) summarize results
pooled from 2 (D–F), 4 (C), 12 (B), and 28 (A) independent experiments; each point (A–D and F) represents one biological replicate including one to six mice. *,
P < 0.05; **, P < 0.01; ***, P < 0.005; ****, P < 0.001; Mann–Whitney test. CPM, counts per minute; Ins-ChgA, insulin–chromogranin A.
Figure 2. B cells are the major MHC-II–expressing APCs in the blood presenting inulin peptides. (A) Blood leukocytes were obtained from 4-wk-old
female NODmice, and theMHC-II (I-Ag7)–bearing cells were analyzed by flow cytometry. Data show representative FACS plots depicting the gating strategy for
identifying different APCs in the blood, including the MHC-II+ B cells, monocytes, pDCs, and conventional DCs. (B) Percentage of the MHC-II+ B cells,
monocytes, pDCs, and conventional DCs, as described in A, among the total CD45+ leukocytes in the blood of 4-wk-old female NOD mice. (C) Responses of the
InsB:13-21– and InsB:12-20–specific CD4 T cells to equal numbers of B cells or non–B cell APCs (regardless of MHC-II expression) isolated fromNODmice given
glucose. (D) Responses of the InsB:13-21– and InsB:12-20–specific CD4 T cells to equal numbers of B cells or non–B cell APCs isolated from NOD mice
(regardless of MHC-II expression) without glucose challenge upon pulse with exogenous InsB:9-23 (10 µM). Data (mean ± SEM) summarize results pooled from
two (B–D) independent experiments; each point represents one biological replicate including three or four mice. *, P < 0.05; Mann–Whitney test. CPM, counts
per minute.
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released from the islets are primarily captured and presented by
the circulating B cells.
Anti-InsB antibodies block the leukocyte presentation and
reduce diabetes incidence
We have previously documented two monoclonal antibodies
specifically recognizing the InsB:9-23 peptide and the entire InsB
(InsB:1-30). These two antibodies did not recognize the conforma-
tional insulinmolecule andwere not cross-reactive (Wan et al., 2018).
Considering that both InsB:9-23 and InsB:1-30 were identified as in-
dividual sequences in the secretome (Wan et al., 2018) and may
therefore provide the InsB:12-20 and InsB:13-21 epitopes, we tested
whether administration of these two antibodies may interfere with
the presentation. We administered the two antibodies a day before
glucose challenge and found a significant blockade of the presentation
to the InsB:12-20– and InsB:13-21–specific T cells by theWBCs (Fig. 3
A). The degree of blockade by the anti-InsB antibodies was compa-
rable to that mediated by the anti–I-Ag7 antibody (Fig. 3 A).
To evaluate whether the blockade of insulin peptide presentation
may influence the autoimmune process, we tested the two anti-InsB
monoclonal antibodies for their long-term effects in diabetes devel-
opment. A weekly dose of the antibodymixture was administered to
female NOD mice at different ages during the prediabetic stage, and
themice were followed until 40 wk of age. A significant reduction of
diabetes incidence was observed in mice recipient of the anti-InsB
antibodies relative to those given the control mouse IgG (Fig. 3 B).
We next examined the influence of the antibodies in modu-
lating immune cell infiltration in islets. The antibody mixture
was given to female NOD mice at the ages of 4, 5, and 6 wk, and
their islets were examined by flow cytometry at the age of 9 wk.
We found an ∼50% reduction of the CD45+ leukocytes in the islets
isolated from mice given the anti-InsB antibodies (Fig. 3 C). Spe-
cifically, the infiltration of the CD4 and CD8 T cells as well as the
DCs was significantly reduced, and the percentage of the islet
resident macrophages was not affected (Fig. 3 D). In sum, specific
monoclonal antibodies blocked the capture of insulin peptides
released from the islets; such a process may translate into im-
munoinhibitory effects that dampened the penetrance of diabetes.
The blood leukocyte MHC-II peptidome includes immunogenic
insulin peptides
The MHC-II peptidome of the blood leukocytes in NOD mice fol-
lowing a glucose challenge was examined in two independent
analyses that included 20 and 40 NOD mice, respectively. Blood
leukocytes were isolated from NOD mice 30 min after glucose
challenge. Following cell lysis, the I-Ag7 molecules were isolated via
antibody binding; the peptides bound to them were eluted and
examined by liquid chromatography–tandem mass spectrometry
(LC-MS/MS). From the two biological samples, 536 peptides were
identified, grouped into 186 overlapping sets or families, each
having differences in their terminal residues (Table S1, Table S2,
and Table S3). In terms of tissue origin, many originated from
plasma proteins, including albumin and hemoglobin, while others
were from proteins ubiquitously expressed.
The β cell–derived proteins included families centered on the
insulin-2 B-chain (Ins2B) and the C-peptide. Of these, the most
abundant were derived from the C-terminal (Ins1C:51-61) and
the N-terminal (Ins1C:37-56) fragments of Ins1C as well as from
Ins2B:9-23 (Table 1, Table S1, Table S2, and Table S3). The InsB
and InsC peptide families were independently identified in both
experiments (Table 1).
At the peptide level, we identified 12 sequences covering
Ins2B:9-23 (Fig. 4), including Ins2B:9-23, Ins2B:11-23, and Ins2B:12-
23. All these three peptides were shown to activate the InsB:12-20–
or InsB:13-21–specific T cells (Wan et al., 2018, 2020). For Ins1C:
51-61, seven peptide sequences were identified (Fig. 4). Most se-
quences varied only by deamidation, a posttranslational modifi-
cation that converts glutamine (Q) to glutamic acid (E), at Q52
and/or Q61; singly deamidated (Q61) and doubly deamidated forms
of the peptide each comprised approximately one third of the
Ins1C:51-61 pool (Fig. 4). Of note, because I-Ag7 favors binding of
peptides having acidic residues at the C terminus (Corper et al.,
2000; Latek et al., 2000; Lee et al., 2001; Suri et al., 2005), the
deamidation change at Q61 enhanced the binding of the Ins1C:51-61
peptide to I-Ag7 (Wan et al., 2020). As a result, the deamidated
Ins1C:51-61 (LQTLALEVARE) elicited a stronger T cell response
than the native version (LQTLALEVARQ; Wan et al., 2020).
MHC-II–bound peptides were also isolated from WBCs of 19
NOD mice without challenging with glucose (Table S4). In
general, fewer peptides belonging to each β cell–derived family
were identified in this sample (Table 1 and Table S4). Moreover,
the relative abundances (normalized to total ion current; see
Materials and methods) of the identified insulin peptides were
lower than those after glucose challenge (Fig. 4). This is con-
sistent with the results of antigen presentation experiments.
Importantly, the peptides identified in the WBC MHC-II pep-
tidome overlapped with our previously published islet and spleen
peptidomes (Wan et al., 2020), with 43/186 families also identified
in islets and 57/186 in the spleen (Table S1). All the β cell–derived
families identified in the WBC peptidome (Table 1) were found in
that of the islet and spleen. We did not find unique β cell peptides
in the WBC peptidome. In particular, many of the Ins2B- and
Ins1C-derived peptides had identical sequences with those pre-
sented in the islets. Identification of the Ins2B peptides with oxi-
dation of cysteine and the InsCs with deamidation (Fig. 4) were
consistent with our findings in islets and spleen peptidome (Wan
et al., 2020). Other common β cell epitopes, including those from
secretogranin and hybrid insulin peptides, were not found in the
WBC peptidome. These families showed a lower abundance than
insulin peptides in the islets (Wan et al., 2020) and may therefore
remain below the limit of detection by MS in the WBCs.
Discussion
This study shows that circulating leukocytes contain immuno-
genic peptide–MHC-II complexes shortly after a glucose challenge.
We demonstrate spontaneous presentation of peptide epitopes
from proinsulin by MHC-II+ blood leukocytes, particularly the
B cells. The documented presentation is specific and pathologically
relevant. The administration of antibodies reactive to InsB pep-
tides blocks the recognition of InsB-derived epitopes and dampens
diabetes development. Moreover, the MHC-II peptidome of
the WBCs contains the major series of β cell–derived peptides
identified in the islets peptidome, including identical sequences
Vomund et al. Journal of Experimental Medicine 5 of 12
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of immunogenic InsB- and InsC-derived peptides. Collectively,
these findings demonstrate that peripheral blood is an acces-
sible site for probing pancreatic islets. In the context of T1D,
this strategy may facilitate the evaluation of disease diagnosis
and pathogenesis.
Examining the WBCs provides a window for assessing the
immunogenic peptides of the target organ. In support of this
concept, elegant studies have shown that blood B cells from
patients withmultiple sclerosis presented self-peptides to brain-
homing CD4 T cells (Jelcic et al., 2018). Such presentation led to
Figure 3. Specific monoclonal antibodies block the presentation of InsB peptides byWBCs and reduce diabetes penetrance. (A) Responses of the InsB:13-
21– and InsB:12-20–specific CD4 T cells to blood leukocytes obtained from NOD mice with or without injection of a mixture of anti–InsB:9-23 and anti–InsB:1-
30 antibodies before glucose challenge. The anti–I-Ag7 antibody was added to the T cell–leukocyte culture as a control. Data (mean ± SEM) summarize results
pooled from three independent experiments; each point represents one biological replicate including two to six mice. ****, P < 0.001; Mann–Whitney test.
(B) Diabetes incidence of female NOD mice administered with the mixture of anti–InsB:9-23 and anti–InsB:1-30 antibodies. The control mice were given
polyclonal mouse IgG. Data summarize the percent of diabetes (21 mice per group) from three independent experiments. **, P < 0.005; log-rank test.
(C and D) Cohorts of female NOD mice were given the anti-InsB antibody mixture or control mouse IgG weekly at 4, 5, and 6 wk of age, and the islets were
analyzed for leukocyte infiltration by flow cytometry at 9 wk of age. (C) Representative FACS plots showing the gating strategy of the immune cell components
in the islets, including the CD45+ leukocytes, CD4 and CD8 T cells, DCs, and the resident macrophages (Mac). (D) Percentage of the indicated immune cell
populations, as depicted in C, among the total islet cells. Data represent results obtained from individual mice (each point) examined in three independent
experiments. *, P < 0.01; **, P < 0.005; Mann–Whitney test. CPM, counts per minute; SSA, side scatter A.
Vomund et al. Journal of Experimental Medicine 6 of 12
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autologous T cell proliferation and depended on the expression
of the HLA-DR15 haplotype (Jelcic et al., 2018; Mohme et al.,
2013; Wang et al., 2020), a major genetic risk factor of multi-
ple sclerosis. DCs carrying antigens from peripheral tissues were
shown to enter the circulation, from where they migrated to the
bone marrow and mediated activation of resident memory
T cells during antigen-specific interactions (Cavanagh et al.,
2005). A recent study identified unexpected T cell–monocyte
doublets in the blood of human individuals; intriguingly, the
frequency and the functional signature of these cell complexes
reflected the immune history of different individuals with in-
fection or immunization (Burel et al., 2019). Future studies that
emphasize the features of the immunopeptidome in the blood
during immunological challenges should be highly informative.
The main APCs spontaneously presenting insulin peptides in
mouse blood are B cells, owing to their high number and ex-
pression of MHC-II. We have documented that the MHC-II
peptidome of B cells purified from the spleen of NOD mice
contained InsB- and InsC-derived peptides (Wan et al., 2020).
These sequences are compatible with those in the WBC pepti-
dome described in this study. These results suggest that blood
B cells may ferry antigens into secondary lymphoid tissues in a
cell-associated manner. Peripheral B cells may also directly ac-
quire antigens via uptake of insulin peptides from the blood.
This was supported by the finding that fluorescently labeled
InsB:9-23 peptide rapidly entered the spleen and bound to I-Ag7+
B cells shortly after intravenous injection (Wan et al., 2018).
Dissecting the antigen sources may facilitate a better under-
standing of the indispensable role of B cells in driving diabetes
development in NODmice (Serreze et al., 1998). The importance
of antigen presentation by B cells was highlighted by previous
studies showing that genetic ablation of I-Ag7 in B cells largely
abolished diabetes onset (Noorchashm et al., 1999). We and
others also demonstrated that presentation of diabetogenic an-
tigens by peripheral B cells assisted T cell autoreactivity (Greeley
et al., 2001; Mariño et al., 2012; Hu et al., 2007; Wan et al., 2016;
Kendall et al., 2013; Henry et al., 2012; Hulbert et al., 2001). It is
tempting to speculate that the capture of islet-derived peptides
by the circulating B cells is an integral component of B cell–
mediated pathogenicity.
We documented that administration of anti-InsB monoclonal
antibodies completely blocked the presentation of the InsB:13-21
and InsB:12-20 epitopes by WBCs. The two monoclonal anti-
bodies were generated by immunizing with InsB:9-23 or InsB:1-
30, respectively; both peptides were identified as independent
sequences released from the islets (Wan et al., 2018). InsB:9-23 is
a well-established pathogenic peptide required for initiation of
the autoimmune process in NOD mice (Nakayama et al., 2005,
2007); in humans with T1D, CD4 T cells reactive to this peptide
have been isolated (Michels et al., 2017). The anti–InsB:9-23
antibody identified crinosomes in the islets, a compartment rich
in short insulin peptides (Wan et al., 2018). The InsB:1-30 pep-
tide derived from denatured insulin andwasmainly found in the
regular insulin granules along with conformational insulin
molecules (Wan et al., 2018). Presentation of this long peptide
did not require internal processing and was able to activate the
type B T cells (Wan et al., 2018). The blockade of the leukocyte
presentation indicates that InsB:9-23 and InsB:1-30 represent
the major native peptides harboring the defined immunogenic
epitopes, which seed the periphery.
The inhibition of diabetes progression by the antibody mix-
ture may result from clearance of the InsB peptides from the cir-
culation. Considering the fast turnover of the peptide–MHC-II
complexes observed in this study, we are testing different protocols
involving persistent administration of the antibodies, which may
result in a better control. Moreover, this finding raises the possi-
bility that combining antibodies directed to other immunogenic
peptides, such as the C-terminal segments of Ins1C, may improve
the therapeutic effects. Whether targeting MHC-I–dependent pep-
tides may exert similar effects remains to be determined.
Table 1. β cell–derived peptide families identified in the MHC-II peptidome of blood leukocytes
Description Protein coverage Sequence Glucose No glucose
Ins1C Ins1C:37–56 PQVEQLELGGSPGDLQTLAL 22, 18 8
Ins2B Ins2B:9–23 SHLVEALYLVCGERG 10, 11 6
Ins1C Ins1C:51–61 LQTLALEVARQ 7, 6 0
Insulin-2 C-peptide Ins2C:37–47 PQVAQLELGGG 2, 2 1
Vitamin D–binding protein Gc:389–405 SPLLKRQLTSFIEKGQE 1, 1 0
60-kD heat shock protein Hspd1:164–183 TPEEIAQVATISANGDKDIG 0, 2 0
Zinc transporter 8 ZnT8:313–322 ILSVHVATAA 0, 1 0
Insulin-2 C-peptide Ins2C:48–58 PGAGDLQTLAL 0, 1 0
MHC-II–bound peptides were isolated from blood leukocytes from NOD mice after glucose challenge and analyzed by LC-MS/MS. The table summarizes all
the peptide families derived from pancreatic β cell proteins. The numbers of the individual peptides belonging to each family identified in mice subjected to a
glucose challenge (two independent experiments) relative to those without glucose challenge (a single experiment) are shown. The two experiments of the
glucose challenge condition used 3 × 107 total blood leukocytes from 20 mice and 7.5 × 107 cells from 40mice, respectively. The experiment of the no glucose
condition used 3 × 107 cells isolated from 19 mice. Columns are as follows: Description, protein name; Protein coverage, gene name and amino acid residues
covered; Sequence, amino acid sequence encompassing all peptides identified for a particular family; Glucose, the number of peptides identified in the
specified family for the two biological replicates of the glucose challenge experiments; and No glucose, peptides identified in the mice that did not receive
glucose.
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Materials and methods
Data availability
TheMS data are available via ProteomeXchangewith the dataset
identifier PXD024400.
Mice
NOD/ShiLtJ (NOD), C57BL/6J (B6), and B6.NOD-(D17Mit21-
D17Mit10)/LtJ (B6g7) mice were originally obtained from The
Jackson Laboratory. Mice were bred and maintained under
specific pathogen–free conditions in our facilities. All experi-
ments were approved by the division of Comparative Medicine
of Washington University School of Medicine in St. Louis (ac-
creditation number A3381-01).
Isolation of blood leukocytes
Mice were fasted overnight, and then administered i.p. 4 g
glucose/kg of body weight in saline solution. After a period of
time, usually 30 min in most experiments, the mice were
Figure 4. Relative abundance of insulin peptides isolated from blood leukocytes. The data show the relative abundance of each individual peptide
sequence derived from the Ins2B:9-23 and Ins1C:51-61 families depicted in Table 1. LC-MS/MS data files of the leukocyte MHC-II peptidome were loaded into
Skyline for quantification of peptides covering the Ins2B:9-23 and Ins1C:51-61 families, and the resulting peak areas were exported, normalized based on the
total ion current, and log2-transformed. The bars represent the normalized log2 abundance of the indicated peptides. The results of the no glucose condition
represent a single experiment analyzing 3 × 107 blood leukocytes from 19 NODmice without glucose challenge. The data of the glucose challenge condition are
from two independent experiments including 20 (3 × 107 cells) and 40 (7.5 × 107 cells) NODmice after glucose injection, respectively. In peptide sequences, the
lowercase c denotes the oxidation of cysteine to cysteic acid, and the lowercase q denotes the deamidation of glutamine.
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anesthetized, and blood was drawn from the heart or from the
eye into a heparinized vessel. To isolate theWBCs, the blood was
mixed with an equal volume of DMEM containing 10% fetal
bovine serum. The diluted blood sample was added to a 15-ml
conical tube and underlaid with an equal volume of Histopaque
1077 (Sigma-Aldrich; #H8889). Samples were spun for 35 min at
400 g. The WBCs were isolated from the interface and washed
twice with PBS.
Treatment with S961 and anti-InsB antibodies
For S961 (Phoenix Pharmaceuticals) treatment, the animals
were injected with 10 nmol in water i.p. 30 min before the
glucose injection. For testing the anti-InsB antibodies in WBC
presentation, mice were injected i.p. with 500 µg each of the two
monoclonal antibodies, anti-InsB:9-23 (clone AIP) and anti-InsB:1-
30 (clone 6F3.B8), or 1 mg of polyclonal mouse IgG (BioXcell), and
18 h later, the mice were challenged with glucose. For treating
diabetes, the antibodymixture (250 µg per antibody per injection)
or mouse IgG (500 µg per injection) was administered i.p. weekly
in female NODmice at the age of 4, 5, 6, 9, 10, 11, 14, 15, and 16 wk.
The mice were monitored for diabetes incidence weekly until the
age of 40wk.Mice with two consecutive readings of blood glucose
>250 mg/dl were considered diabetic. For testing islet infiltration,
the antibody mixture (250 µg per antibody per injection) or
mouse IgG (500 µg per injection) was given i.p. weekly in female
NODmice at the ages of 4, 5, and 6wk. Themicewere sacrificed at
the age of 9 wk, and the islets were examined by flow cytometry.
Enrichment of B cells and non–B cell APC populations from
blood
WBCs were harvested as described and were first depleted of
T cells by anti-CD3 magnetic beads (Miltenyi Biotec). B cells
were then positively selected for using anti-CD19 magnetic
beads (Miltenyi Biotec). The unbound cells containing non–B cell
APCs were subjected to a second round of CD19 selection to re-
move the residual B cells. Flow cytometry analysis showed high
(>95%) purity of the B cells and the non–B cell APCs (monocytes,
pDCs, and DCs).
Antigen presentation assays
Isolated WBCs (105 per well in 96-well plates) were cultured
overnight with a variety of different T cell hybridomas (5 ×
104 per well): IIT-3 (InsB:13-21), 9B9 (InsB:12-20), 3526–51
(Ins1C:51-61), BDC2.5 (insulin–chromogranin A), clone 58
(InsB:11-25), and 8.3 (IGRP 206–214). The T cell responses
were probed by IL-2 production measured by culturing su-
pernatants in the presence of the IL-2–dependent cell line
CTLL-2. The proliferation of CTLL-2 cells was measured by
the incorporation of 3H-thymidine.
Isolation of pancreatic islets
Upon exposure of the pancreas, the duodenum ampulla was
clamped under a dissection microscope. Via the common bile
duct, the pancreas was inflated with 5 ml calcium-free Hank’s
balanced salt solution containing type XI collagenase (0.4 mg/
ml; Sigma-Aldrich). The pancreas was then excised and digested
for 15 min at 37°C. The digestion mixture was briefly shaken for
90 s and passed through a 70-µm cell strainer. The islet-
containing fraction retained by the strainer was flushed into a
Petri dish for handpicking. The handpicked islets were dispersed
into single-cell suspensions by incubating in the enzymatic-free
cell dissociation solution (Sigma-Aldrich) for 3 min at 37°C. Islet
isolation was performed in individual mice, which generated
∼100 islets per mouse. All the islets isolated from the same
mouse were pooled as one biological sample for subsequent
examination.
Flow cytometry analysis
Cell suspensions were prepared from blood leukocytes or dis-
persed islet cells. The cells were incubated in a PBS-based buffer
containing 0.5% BSA and 2.4G2 antibody (10 µg/ml) for 20 min
on ice to block Fc receptors. The following antibodies purchased
from Biolegend were used to stain the cells for 25 min on ice in
the same buffer: Brilliant violet–anti-CD45 (30-F11), PE–anti-
Thy1.2 (30-H12), PE–anti-CD49b (HMα2), PE–anti-Ly6G (1A8),
FITC–anti-B220 (RA3-6B2), PerCP-Cy5.5–anti-Ly6C (HK1.4), APC-
Cy7–anti-CD11c (N418), PE-Cy7–anti-CD11b (M1/70), APC–anti-
SiglecH (551), FITC–anti-CD4 (RM4-5), Pacific Blue–anti-CD8a
(53–6.7), and APC–anti-F4/80 (BM8). The anti–I-Ag7 antibody
(clone AG2.42.7) was generated in the laboratory and conjugated
to Pacific Blue using a labeling kit (Invitrogen; P30012). The cells
were washed twice and acquired using a FACSCanto II (BD Bio-
sciences), and data were analyzed using FlowJo software (Tree
Star).
Isolation of MHC-II peptidome
We followed our original procedure (Wan et al., 2020), with
modifications. The WBCs were suspended in lysis buffer
(40 mM N-octanoyl-N-methylglucamine, 40 mM N-nonanoyl-
N-methylglucamine, 1 mM phenylmethylsulfonyl fluoride,
0.2 mM iodoacetamide, 20 µg ml−1 leupeptin, and Roche cOm-
plete Mini Protease cocktail in PBS) and rocked for 1 h at 4°C.
The cell lysate was spun in a centrifuge at 20,000 g for 30min at
4°C. To eliminate nonspecific binding of peptides, the superna-
tant was first incubated with polyclonal mouse IgG (1.5 mg an-
tibody per sample; Bio X Cell) bound to sepharose 4B at 4°C for
30 min. The unbound material containing MHC-II–peptide
complexes was collected and was then added to a tube con-
taining PBS-washed sepharose conjugated to the anti–I-Ag7 an-
tibody (1.5 mg per sample; AG2.42.7) and incubated at 4°C
overnight. The I-Ag7–sepharose was applied to a column and
washed four times as follows: 10 ml 150 mM NaCl and 20 mM
Tris, pH 7.4; 10 ml 400 mM NaCl and 20 mM Tris, pH 7.4; 10 ml
150mMNaCl and 20mMTris, pH 7.4; and 10ml 20mMTris, pH
8.0. Peptides were eluted with 10% acetic acid and dried with a
SpeedVac. Eluted peptides were passed over detergent removal
spin columns (Pierce) to remove traces of remaining detergent
and were cleaned using C18 Spin Columns from Thermo Fisher
Scientific (Pierce).
MS analysis and data analysis
A Dionex UltiMate 1000 system (Thermo Fisher Scientific) was
coupled to an Orbitrap Fusion Lumos (Thermo Fisher Scientific)
through an Easy-Spray ion source (Thermo Fisher Scientific).
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Peptide samples were dissolved in 2% acetonitrile/0.1% formic
acid (20 µl), loaded (19 µl, 15 µl/min, 3 min) onto a trap column
(100 µm × 2 cm, 5 µm Acclaim PepMap 100 C18, 50°C), eluted
(0.200 µl/min) onto an Easy-Spray PepMap RSLC C18 column
(2 µm, 50 cm × 75 µm inner diameter, 50°C; Thermo Fisher
Scientific), and separated with the following gradient, all per-
centages of buffer B (0.1% formic acid in acetonitrile): 0–110min,
2–22%; 110–120 min, 22–35%; 120–130 min, 35–95%; 130–150
min, isocratic at 95%; 151–153 min, 95–2%; 153–171 min, isocratic
at 2%. Spray voltage was 1,900 V, ion transfer tube temperature
was 275°C, and radio frequency lens was 30%. MS scans were
acquired in profile mode andMS/MS scans in centroidmode, for
ions with charge states 2–5, with a cycle time of 3 s. MS spectra
were recorded from 375 to 1,500 daltons at 120,000 resolution
(at mass to charge 200), and higher energy collision-induced
dissociation MS/MS was triggered above a threshold of 2.0e4,
with quadrupole isolation (0.7 daltons) at 30,000 resolution, and
collision energy of 30%. Dynamic exclusion was used (±5 parts
per million, 60 s), and monoisotopic precursor selection was on.
MS data analysis and quantification
Data files were uploaded to PEAKS X+ (version 10.5; Bio-
informatics Solutions) for processing, de novo sequencing, and
database searching (Tran et al., 2019). Resulting sequences were
searched against the UniProt Mouse database (downloaded January
12, 2019; 17,000 entries) appendedwith the Common Repository for
Adventitious Proteins contaminant database, with mass error tol-
erances of 10 parts per million and 0.01 daltons for parent and
fragment, respectively, no enzyme specificity and methionine oxi-
dation, deamidation of glutamine and asparagine, and oxidation of
cysteine to cysteic acid as variable modifications. False discovery
rate estimation was enabled, and filters were adjusted to give a 1%
false discovery rate at the peptide level unless otherwise noted.
To measure peptide abundances, data files were imported
into Skyline (64 bit, version 20.1.0.155 [a0e7323e3], MacCoss
Laboratory, University ofWashington; Schilling et al., 2012). The
resulting abundances were exported, normalized to the total ion
current, log2 transformed, and plotted in SigmaPlot 13.0 (build
13.0.0.83; Systat Software).
Statistics
The Mann–Whitney test was used to determine the statistical
differences between two experimental groups with unpaired
biological replicates. The log-rank test was used to determine the
significant difference in diabetes incidence.
Online supplemental material
Table S1 summarizes all the peptide families identified in the
blood leukocytes fromNODmice with or without challenge with
glucose. Table S2 summarizes all the individual peptides iden-
tified in the MHC-II peptidome of the blood leukocytes isolated
from 40 NODmice after glucose challenge. Table S3 summarizes
all the individual peptides identified in the MHC-II peptidome of
the blood leukocytes isolated from 20 NOD mice after glucose
challenge. Table S4 summarizes all the individual peptides
identified in the MHC-II peptidome of the blood leukocytes
isolated from 10 NOD mice without glucose challenge.
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Supplemental material
Four tables are provided online as separate Excel files. Table S1 is a compiled list of peptide families identified in WBCs isolated
from NOD mice, both with (NOD_40 mice and NOD_20 mice) and without (control_19 mice) glucose challenge. The number in each
column indicates the number of peptides identified. Table S2 is a list of MHC-II peptides identified by LC-MS/MS from PBMCs
isolated from NODmice after glucose challenge (40 mice). Table S3 is a list of MHC-II peptides identified by LC-MS/MS from PBMCs
isolated from NODmice after glucose challenge (20 mice). Table S4 is a list of MHC-II peptides identified by LC-MS/MS from PBMCs
isolated from NOD mice without glucose challenge (control).
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